Human papillomavirus vaccine recombinant bivalent - GlaxoSmithKline/MedImmune

Drug Profile

Human papillomavirus vaccine recombinant bivalent - GlaxoSmithKline/MedImmune

Alternative Names: Cervarix; GSK Biologicals HPV-16/18 vaccine; GSK Biologicals' HPV vaccine (GSK-580299); GSK-580299; MEDI 517; MEDI-517 HPV-16/18 VLP AS04 vaccine

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator MedImmune
  • Developer GlaxoSmithKline
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections

Most Recent Events

  • 01 Feb 2016 GlaxoSmithKline completes a phase III trial for Human papillomavirus infections and Cervical intraepithelial neoplasia (Prevention) in China (NCT00779766)
  • 01 Jul 2015 GlaxoSmithKline terminates a phase III trial in Cervical intraepithelial neoplasia in Russia prior to enrolment initiation (NCT02082639)
  • 10 Jun 2015 Human papillomavirus vaccine recombinant bivalent - GlaxoSmithKline/MedImmune is still in phase III trials for the prevention of Cervical cancer, Cervical intraepithelial neoplasia and Human papillomavirus infections (In children) in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top